Výsledky léčby gefitinebem (Iressou) u 89 nemocných s pokročilým nemalobuněčným karcinomem plic (NSCLC)

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Title in English	Results of gefitinib (Iressa) treatment of 89 patients with advanced non-small cell lung cancer (NSCLC)
Authors	SKŘIČKOVÁ Jana TOMÍŠKOVÁ Marcela SVOBODNÍK Adam KAPLANOVÁ Jana PÁLKOVÁ Ivana KADLEC Bohdan BABIČKOVÁ Lenka STRATIL Dalibor NEBESKÝ Tomáš
Year of publication	2005
Type	Article in Proceedings
Conference	Edukační sborník
MU Faculty or unit	Faculty of Medicine
Citation
Field	Pneumology
Keywords	non-small cell lung cancer (NSCLC); treatment; gefinitib
Description	The results of the first 89 NSCLC patients treated with gefinitib (Iressa)are presented. The treatment started between Feb 2002 and Aug 2004 In Jan 2005, the median survival was 10.3 months in the group with perfomance status 1. In 39% (44 pats) stabilization was achieved, in 8 (9%) partial remission was confirmed. Complete remission occurred in none. Overall, the tolerance of the drug was very good.
Related projects:	Environment - carcinogenesis - oncology